Serum levels of soluble Fas/APO-1 receptor are increased in systemic sclerosis

Archives of Dermatological Research

Volumn 290, Issue 4, 1998, Pages 187-190

  Wetzig, T ^a   Petri, J B ^a   Mittag, M ^a   Haustein, U F ^a  

^a UNIVERSITY OF LEIPZIG   (Germany)

Author keywords

Apoptosis; Autoimmune disease; CD95; SFas; Systemic sclerosis

Indexed keywords

FAS ANTIGEN; RECEPTOR;

ADULT; APOPTOSIS; ARTICLE; BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; INFLAMMATORY DISEASE; LUPUS ERYTHEMATOSUS; MALE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RHEUMATIC DISEASE; SYSTEMIC SCLEROSIS; T LYMPHOCYTE;

ANTIBODIES, ANTINUCLEAR; APOPTOSIS; AUTOANTIBODIES; CENTROMERE; DNA TOPOISOMERASES, TYPE I; FAS LIGAND PROTEIN; FEMALE; HUMANS; MALE; MEMBRANE GLYCOPROTEINS; MIDDLE AGED; REFERENCE VALUES; SCLERODERMA, SYSTEMIC; SOLUBILITY;

EID: 0031745129     PISSN: 03403696     EISSN: None     Source Type: Journal    
DOI: 10.1007/s004030050288     Document Type: Article

References (27)

1. Aggarwal BB, Singh S, LaPushin R, Totpal K (1995) Fas signals proliferation of normal human diploid fibroblast and its mechanism is different from tumor necrosis factor receptor. FEBS Lett 364:5-8
2. Ashany D, Lacy E, Nicolic-Zugic J, Friedman SM, Elkon KB (1995) Th1 CD4+ lymphocytes delete activated macrophages through the Fas/APO-1 antigen pathway. Proc Natl Acad Sci USA 92: 11225-11229
3. Black CM (1993) The aetiopathogenesis of systemic sclerosis. J Intern Med 234:3-8
4. Black CM, Dalton CP (1995) The management of systemic sclerosis. Brit J Rheum 34:3-7
5. Bruns M, Herrmann K, Haustein UF (1994) Immunological parameters in systemic sclerosis. Int J Dermatol 33:25-32
6. Cheng J, Zhou T, Liu C, Shapiro JP, Brauer MJ, Kiefer MC, Barr PJ, Mountz JD (1994) Protection from Fas-mediated apoptosis by a soluble form of Fas molecule. Science 263: 1759-1762
7. Dhein J, Walczak H, Baumler C, Debatin K-M, Krummer PH (1995) Autocrine T-cell suicide mediated by APO-1 (Fas/ CD95). Nature 373:438-441
8. Goel N, Ulrich DT, St. Clair W, Fleming JA, Lynch DH, Seldin MF (1995) Lack of correlation between serum soluble Fas/APO-1 levels and autoimmune disease. Arthritis Rheum 38: 1738-1743
9. Haustein UF (1996) Autoimmunerkrankungen und Störungen der Immunregulation und des programmierten Zelltodes (Apoptose) In: Haase G, Eicheler E (eds) Wege und Fortschritte der Wissenschaft. Akademie Verlag, Berlin, pp 699-707
10. Haustein UF, Herrmann K, Bruns M (1992) Collagen metabolism in systemic sclerosis. Eur Acad Derm Venereol 1:37-42
11. Heaney ML, Golde DW (1996) Soluble cytokine receptors. Blood 87:847
12. Jiang JD, Schlesinger M, Sacks H, Mildvan D, Roboz JB, Bekesi JG (1997) Concentration of soluble CD95 and CD8 antigens in the plasma and levels of CD8+CD95+, CD8+CD38+, and CD4+CD95+ T cells are markers for HIV-1 infection and clinical status. J Clin Immunol 17(2):185-192
13. Kahari VM (1994) Activation of dermal connective tissue in sclerodenna. Ann Intern Med 25:511-518
14. Knipping E, Krummer PH, Onel KB, Lehman TJA, Mysler E, Elkon KB (1995) Levels of soluble Fas/APO-1/CD95 in systemic lupus erythemalosus and juvenile rheumatoid arthritis. Arthritis Rheum 38:1735-1737
15. Kulozik M, Scharfetter K, Lankat-Buttgereit B, Heckmann M, Krieg T (1990) Colocalization of transforming growth factor β2 with α1(I) procollagen mRNA in tissue sections of patients with systemic sclerosis. J Clin Invest 86:917-922
16. LeRoy EC (1974) Increased collagen synthesis by scleroderma fibroblasts in vitro. J Clin Invest 54:880-889
17. LeRoy EC, Black C, Fleischmajer R, Jablonska S, Krieg T, Medsger TA, Rowell N, Wollheim F (1988) Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 15:202-208
18. Nagata S (1995) Fas and Fas ligand: a death factor and its receptor. Adv Immunol 57:129-144
19. Nozawa K, Kayagaki N, Takano Y, Yagita H, Okumura K, Hasimoto H (1997) Soluble Fas (apo-1, CD95) and soluble Fas ligand in rheumatic diseases: Arthritis Rheum 40:1126-1129
20. Rathmell JC, Cooke MP, Ho WY, Grein J, Townsend SE, Davis MM, Godnow CC (1995) CD95 (Fast-dependent elimination of self-reactive B cells upon interaction with CD4+ T cells. Nature 376:181-184
21. Schneider P, Bodner J-L, Holler N, Mattmann C, Scuderi P, Terskikh A, Peitsch MC, Tschopp J (1997) Characterisation of Fas (Apo-1, CD 95)-Fas ligand interaction. J Biol Chem 272: 18827-18833
22. Sollberg S, Krieg T (1996) New aspects in scleroderma research. Int Arch Allergy Immunol 111:330-336
23. Subcommittee for Scleroderma criteria, American Rheumatism Association. Diagnostic and Therapeutic Criteria Committee (1980) Preliminary criteria for classification of systemic sclerosis. Arthritis Rheum 23:581-590
24. Suda T, Takahashi T, Golstein P, Nagata S (1993) Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family. Cell 75:1169-1178
25. Takahashi T, Tanaka M, Brannan CI, et al (1994) Generalised lymphoproliferative disease in mice, caused by a point mutation in the Fas ligand. Cell 76:969-976
26. Takano Y, Miyake S, Kayagaki N, Nozawa K, Morimoto S, Azuma M, Yagita H, Takasaki Y, Okumura K, Hashimoto H (1996) Soluble Fas molecule in the serum of patients with systemic lupus crythematodus. J Clin Immunol 16:261-265
27. Watanabe-Fukunaga R, Brannan CI, Copeland NG, Jenkins NA, Naguta S (1992) Lymphoproliferation disorder in mice explained by defects in Fas antigen that mediates apoptosis. Nature 356:314-317